Curi RMB Capital LLC Sells 51 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Curi RMB Capital LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,571 shares of the company’s stock after selling 51 shares during the quarter. Curi RMB Capital LLC’s holdings in IDEXX Laboratories were worth $2,815,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Empowered Funds LLC increased its position in IDEXX Laboratories by 28.0% during the first quarter. Empowered Funds LLC now owns 1,039 shares of the company’s stock valued at $561,000 after acquiring an additional 227 shares during the last quarter. Avantax Advisory Services Inc. boosted its position in shares of IDEXX Laboratories by 24.5% during the first quarter. Avantax Advisory Services Inc. now owns 787 shares of the company’s stock worth $425,000 after acquiring an additional 155 shares during the last quarter. Orion Portfolio Solutions LLC boosted its holdings in shares of IDEXX Laboratories by 3.1% during the 1st quarter. Orion Portfolio Solutions LLC now owns 3,001 shares of the company’s stock valued at $1,620,000 after purchasing an additional 91 shares during the last quarter. Intech Investment Management LLC grew its holdings in IDEXX Laboratories by 154.2% during the 1st quarter. Intech Investment Management LLC now owns 4,090 shares of the company’s stock valued at $2,208,000 after buying an additional 2,481 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of IDEXX Laboratories by 1.2% in the first quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock valued at $4,576,476,000 after purchasing an additional 98,387 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.6 %

IDXX stock opened at $420.91 on Friday. The company has a market capitalization of $34.47 billion, a P/E ratio of 40.59, a price-to-earnings-growth ratio of 3.75 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $404.74 and a 12 month high of $583.39. The firm’s fifty day simple moving average is $469.35 and its 200-day simple moving average is $483.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm’s revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.53 earnings per share. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IDXX shares. Piper Sandler reissued a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Barclays lowered their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. BTIG Research started coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Finally, JPMorgan Chase & Co. lowered their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.